viimane versioon :
19/11/2024
vähiravimite   Vincristine sulfate  
Süsteravim
Stabiilsus lahustes Stabiilsust mõjutavad tegurid stabiilsust mõjutavad faktorid Sobimatus Manustamis viis Viited pdf
   keemiline struktuur  

Kaubanduslikud nimed erinevates maades   Kaubanduslikud nimed erinevates maades     

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Cellecristin Saksamaa
Citomid Kolumbia, Maroko, Mehhiko, Tšiili
Crisovin Ecuador, Kolumbia, Mehhiko
Cytocristin Malaisia
DBL vincristine sulfate Malaisia, uus-Meremaa
Farmistin Saksamaa
Marqibo Ameerika ühendriigid
Nefixol Mehhiko
Oncocristin Kolumbia
Oncovin Araabia Ühendemiraadid, Austria, Kolumbia, Luksemburg, Maroko, Mehhiko, Prantsusmaa, Rootsi, Saudi Araabia, Soome, Suurbritannia, Sveits, Taani
Onkocristin Saksamaa
Sindovin Iraan
Sulfato de vincristine Venetsueela
Unicristin Maroko
Vinblax Mehhiko
Vincasar Ameerika ühendriigid, Mehhiko
Vincrisin Belgia
Vincristin Austria, Saksamaa, Sveits, Ungari
Vincristina Argentiina, Ecuador, Hispaania, Iraan, Island, Itaalia, Kolumbia, Maroko, Tšiili, Venetsueela
Vincristine Kreeka, Luksemburg, Malaisia, Maroko, Norra, Prantsusmaa, Rootsi, Sveits, Tuneesia, Türgi
Vincristine sulfat Türgi
Vincristine sulfate Ameerika ühendriigid, Kanada
Vincristine sulphate Araabia Ühendemiraadid, Egiptus, Iirimaa, Malaisia, Poola, Suurbritannia, uus-Meremaa
Vincristinesulfaat Holland
Vincristinum Luksemburg
Vincrisul Hispaania
Vinlon Lyo Maroko
Vinracine Egiptus, Malaisia
Vintec Mehhiko
Viited   Süsteravim   Viited : Vincristine sulfate  
tüüp avaldamine
3 ajaleht Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
26 ajaleht Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL.
Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags.
Am J Health-Syst Pharm 1997 ; 54: 915-920.
32 ajaleht Nyhammar EK, Johansson SG, Seiving BE.
Stability of doxorubicin and vincristine sulfate in two portable infusion-pump reservoirs.
Am J Health-Syst Pharm 1996 ; 53: 1171-1173.
57 ajaleht Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81 ajaleht Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 ajaleht Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 ajaleht Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
144 ajaleht Dine T, Luyckx M, Cazin JC, Goudaliez F, Mallevais ML.
Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags.
Int J Pharm 1991 ; 77: 279-285.
150 ajaleht Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35.
167 ajaleht Francomb MM, Ford JL, Lee MG.
Adsorption of vincristine, vinblastine, doxorubicin and mitoxantrone to in-line intravenous filters.
Int J Pharm 1994 ; 103: 87-92.
169 ajaleht Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
244 ajaleht Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 ajaleht Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 ajaleht Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 ajaleht Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307 ajaleht Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 ajaleht Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 ajaleht Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
408 ajaleht Beijnen JH, Neef C, Meuwissen OJAT, Rutten JJMH, Rosing H, Underberg WJM.
Stability of intravenous admixtures of doxorubicin and vincristine.
Am J Hosp Pharm 1986 ; 43: 3022-3027.
431 ajaleht McRae MP, King JC.
Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures.
Am J Hosp Pharm 1975 ; 33: 1010-1013.
481 ajaleht Beijnen JH, Vendrig DEMM, Underberg WJM.
Stability of vinca alkaloid anticancer drugs in three commonly used infusion fluids.
J Parenter Sci Technol 1989 ; 43: 84-87.
491 ajaleht Turowski RC, Durthaler JM.
Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2181-2184.
492 ajaleht Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
703 ajaleht Butler LD, Munson JM, DeLuca PP.
Effect of inline filtration on the potency of low-dose drugs.
Am J Hosp Pharm 1980 ; 37: 935-941.
763 ajaleht Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH.
Drug precipitation within IV tubing : A potential hazard of chemotherapy administration.
Cancer Treat Rep 1985 ; 69: 1325-1326.
857 ajaleht Kanke M, Eubanks JL, DeLuca PP.
Binding of selected drugs to a “treated” inline filter.
Am J Hosp Pharm 1983 ; 40: 1323-1328.
905 ajaleht Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 ajaleht Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1026 ajaleht Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881.
1033 ajaleht Wolfe JL, Thoma LA, Du C, Goldspiel BR, Gallelli JF, Grimes GJ, Potti GK.
Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection.
Am J Health-Syst Pharm 1999 ; 56: 985-989.
1408 ajaleht Priston MJ, Sewell GJ.
Stability of three cytotoxic drugs infusions in the Graseby 9000 ambulatory infusion pump.
J Oncol Pharm Practice 1998 ; 4: 143-149.
1410 ajaleht Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1423 ajaleht Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1496 ajaleht Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1520 Labor Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1602 ajaleht Trissel LA, Zhang Y, Cohen MR.
The stablity of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection.
Hosp Pharm 2001 ; 36: 740-745.
1606 ajaleht Yuan P, Grimes GJ, Shankman SE, Daniels CE, Goldspiel BR, Potti GK.
Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection.
Am J Health-Syst Pharm 2001 ; 58: 594-598.
1625 ajaleht Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 ajaleht Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1925 ajaleht Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953 ajaleht Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982 ajaleht Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2094 ajaleht Trittler R.
Stability of intravenous admixtures of doxorubicin and vincristine confirmed by LC-MS.
EJHP Science 2006 ; 12, 1: 10-12.
2247 ajaleht Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
3119 plakat Henriet Th, El Kateb N, Jourdan N, Faure P, Bellenger P.
Stabilité de la vincristine sans conservateurs.
Congrès HOPIPHARM 2010
3214 ajaleht Trittler R, Sewell G.
Stability of vincristine (TEVA) in original vials after re-use in dilute infusions in polyolefin bags and in polypropylene syringes.
EJOP 2011 ; 5,1: 10-14.
3578 Labor Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3644 Labor Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
4102 ajaleht Svirskis D, Behera S, Naidoo N, Beachman J, Raina T, Zhou Y, Berkahn L, Costello I, Gu Y.
Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastromeric pump supporting transition of the EPOCH regimen to oupatient care.
J Oncol Pharm Practice 2018 ;25,4:831-840.

  Mentions Légales